CDW's (SGX:BXE) subsidiary, A Biotech's joint research with Neoregen for next-generation Lipid Nanoparticle (LNP) technology, reached the in vivo phase after positive results from the in vitro research phase, according to a filing with the Singapore Exchange on Tuesday.

The research is aimed at the development of mRNA vaccines and other treatments that can be used in cancer treatment and gene therapy.

The latest phase is expected to last around one year, and if successful, will allow CDW and Neoregen to license out the technology and enter into licensing negotiations with pharmaceutical companies.